Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Arsenic trioxide + Itraconazole |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Arsenic trioxide | Trisenox | ATO | GLI1/2 inhibitor 6 | Trisenox (arsenic trioxide) has multiple mechanisms of action, including inhibition of Gli1 and Gli2 transcription factors (PMID: 26891329). Trisenox (arsenic trioxide) is FDA approved for patients with acute promyelocytic leukemia with PML-RARA translocations (FDA.gov). |
| Itraconazole | Hyphanox | ITC | mTOR Inhibitor 51 | Itraconazole is an antifungal, which indirectly targets mTOR (PMID: 20176935). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02699723 | Phase I | Arsenic trioxide + Itraconazole | Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer | Withdrawn | 0 |